Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
——
Arcus Biosciences logo
Arcus BiosciencesRCUS
——
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.25B+1,531%
Enterprise value$2.33B+874%
P/S40.5×+38.9×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's available for sale securities debt securities current?
Nektar Therapeutics (NKTR) reported available for sale securities debt securities current of $419.03M in Q1 2026.
How has Nektar Therapeutics's available for sale securities debt securities current changed year-over-year?
Nektar Therapeutics's available for sale securities debt securities current increased by 133.1% year-over-year, from $179.74M to $419.03M.
What is the long-term trend for Nektar Therapeutics's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Nektar Therapeutics's available for sale securities debt securities current has grown at a -23.2% compound annual growth rate (CAGR), from $862.94M to $230.64M.